<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17405" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alprostadil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Conemaugh Memorial Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Omar A.</given-names>
          </name>
          <aff>University of Medicine &#x00026; Health Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17405.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alprostadil is a medication used in the management and treatment of erectile dysfunction in males and for temporary patency of ductus arteriosus in newborns with congenital heart diseases before surgical intervention. It is in the prostaglandin analog class of medications. This activity reviews the indications, action, and contraindications for alprostadil as a valuable agent in the therapy of erectile dysfunction in males and presurgical management for newborns with congenital heart diseases with ductus arteriosus dependent circulation. This activity will also highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of those conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the indications for alprostadil.</p></list-item><list-item><p>Describe the adverse effects and contraindications of alprostadil.</p></list-item><list-item><p>Identify the appropriate monitoring and toxicity of alprostadil.</p></list-item><list-item><p>Summarize interprofessional team strategies for enhancing care coordination and communication to advance the management of conditions that can be treated with alprostadil and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17405&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17405">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17405.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Over 150 million people worldwide are affected by erectile dysfunction.&#x000a0;Alprostadil is an approved second-line treatment for erectile dysfunction (oral phosphodiesterase-5 inhibitors like sildenafil are first-line therapy).<xref ref-type="bibr" rid="article-17405.r1">[1]</xref> Another option is using alprostadil in combination with other medications, the combination of papaverine, phentolamine, and alprostadil, known as "trimix," is particularly effective when used for intracavernous injection as a treatment for erectile dysfunction (ED). However, it is only available from compounding pharmacies authorized to produce such extemporaneous dosage forms as it is otherwise not produced commercially.<xref ref-type="bibr" rid="article-17405.r2">[2]</xref></p>
        <p>Alprostadil can also be a therapeutic option for the temporary ductus arteriosus patency maintenance in heart conditions where duct patency is mandated for survival until the defect is corrected surgically. The defects are both cyanotic (e.g., TGA - transposition of great vessels, TOF - tetralogy of Fallot, tricuspid atresia, pulmonary stenosis, etc.) and acyanotic (e.g., coarctation of the aorta, interruption of the aortic arch).<xref ref-type="bibr" rid="article-17405.r3">[3]</xref><xref ref-type="bibr" rid="article-17405.r4">[4]</xref> Alprostadil IV is FDA-approved for the temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery. Alprostadil causes vasodilation by a direct effect on vascular and ductus arteriosus smooth muscle. In infants exhibiting restricted systemic blood flow, alprostadil can increase systemic blood pressure, and decrease the pulmonary artery pressure to aortic pressure ratio. Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. Lipo-PGE1 can effectively improve the neural function of patients with DPN.<xref ref-type="bibr" rid="article-17405.r5">[5]</xref></p>
        <p>Topical alprostadil has also shown promising results for the treatment of FSAD (female sexual arousal disorder) when used in a clinic on females with female sexual arousal disorder, but additional studies are necessary to define further a proper role of topical alprostadil in the treatment of FSAD.<xref ref-type="bibr" rid="article-17405.r6">[6]</xref> Alprostadil is widely used to manage ischemic changes in patients with Raynaud phenomena.<xref ref-type="bibr" rid="article-17405.r7">[7]</xref> Prostaglandin E1 analogs have shown to be efficacious as a modality for conservative treatment for patients with lumbar spinal canal stenosis.<xref ref-type="bibr" rid="article-17405.r8">[8]</xref> Contrast-induced nephropathy (CIN) is one of the top five leading causes of hospital-acquired acute renal injury, using alprostadil has been shown to reduce the precontrast serum creatinine (SCr), blood urea nitrogen (BUN) levels, and a decrease in the incidence of contrast-induced nephropathy (CIN).<xref ref-type="bibr" rid="article-17405.r9">[9]</xref></p>
      </sec>
      <sec id="article-17405.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Alprostadil is a synthetic analog of prostaglandin E1 (PGE1) and shows a multifariousness of pharmacologic actions. Alprostadil binds as an agonist to prostaglandin receptors, e.g., EP2 which in turns activates adenylate cyclase leading to accumulation of 3'5'-cAMP (cyclic adenosine monophosphate) which is responsible for the pharmacologic effects of the medication including smooth muscle relaxation, causing vasodilation (increasing peripheral blood flow; helps in erectile dysfunction) and bronchodilation, and inhibits platelet aggregation.<xref ref-type="bibr" rid="article-17405.r10">[10]</xref></p>
      </sec>
      <sec id="article-17405.s4" sec-type="Administration">
        <title>Administration</title>
        <list list-type="order">
          <list-item>
            <p>Intracavernous alprostadil is useful for its vasodilating properties, which act by relaxing the smooth muscle of the corpus cavernosum, hence increasing the diameter of the cavernous arteries leading to an erection. After intracavernous administration of alprostadil, it is either metabolized locally or&#x000a0;via&#x000a0;the lungs after&#x000a0;being absorbed systematically. Short-term trials have shown that using alprostadil by an intracavernous route is equal to if not superior in inducing erection as compared to other drugs used via intracavernous routes such as papaverine or the combination therapy of papaverine and phentolamine, linsidomine, and topical nitroglycerine (glyceryl trinitrate). If used in therapeutic dosages, most patients tolerate intracavernous alprostadil well. Some potentially severe side effects of intracavernous alprostadil are priapism (4%) and fibrosis (8%).<xref ref-type="bibr" rid="article-17405.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Topical alprostadil therapy is associated with a high rate of discontinuation, as are intracavernosal or transurethral therapies, which are inconvenient and invasive.<xref ref-type="bibr" rid="article-17405.r12">[12]</xref>&#x000a0; Several studies, including four double-blind, placebo-controlled, phase II trials, show that alprostadil topical cream is efficacious and well-tolerated in ED patients with mild-to-severe symptoms, in those undergoing treatment for cardiovascular diseases and diabetes mellitus and in otherwise healthy ED patients. Thus, alprostadil topical cream is a potential first-choice alternative for ED patients who do not respond or who cannot tolerate or do not accept PDE-5 inhibitor therapy.</p>
          </list-item>
          <list-item>
            <p>Intraurethral suppository/medicated urethral system for erection (muse) - alprostadil can be used as an&#x000a0;intraurethral suppository or medicated urethral system for erection, but have shown to be less efficient in inducing cavernous smooth muscle relaxation and also have more side effects such as penile pain/burning, hypotension, and urethral bleeding. This is why self-injection therapy with alprostadil is still considered the first-line therapy/gold standard for the management of erectile dysfunction. The intraurethral suppository is usually only for patients who have refractory erectile dysfunction.<xref ref-type="bibr" rid="article-17405.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Alprostadil cream is an option with vacuum devices with an elastic ring placed at the base of the penis to achieve sufficient rigidity to maintain an erection for satisfactory penetration.<xref ref-type="bibr" rid="article-17405.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Intravenous prostacyclin (PGI2) analogs have shown to be more effective than aspirin for dealing with the rest pain and healing the ischaemic ulcers in Buerger disease.<xref ref-type="bibr" rid="article-17405.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17405.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>When used as an&#x000a0;intraurethral suppository (medicated urethral system for erection)<xref ref-type="bibr" rid="article-17405.r16">[16]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urethral strictures&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Penile/urethral pain</p>
          </list-item>
          <list-item>
            <p>Priapism/prolonged erection</p>
          </list-item>
          <list-item>
            <p>Penile fibrosis</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
        </list>
        <p>Side effects of alprostadil on intracavernosal use:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypotension/hypertension</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Prolonged erection/priapism is less common</p>
          </list-item>
          <list-item>
            <p>Rash on the penis</p>
          </list-item>
          <list-item>
            <p>Swelling of the penis</p>
          </list-item>
          <list-item>
            <p>Penile infections</p>
          </list-item>
          <list-item>
            <p>Injuries to the penis including hematoma formation at the site of the injection</p>
          </list-item>
        </list>
        <p>Side effects of prostaglandin E1 analog (alprostadil) on intravenous use:</p>
        <list list-type="bullet">
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Hypotension/hypertension</p>
          </list-item>
          <list-item>
            <p>Tachycardia/bradycardia</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Electrolyte imbalances such as hypokalemia</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal upset</p>
          </list-item>
          <list-item>
            <p>Infection at the injection site or even sepsis</p>
          </list-item>
          <list-item>
            <p>Pain at the injection site</p>
          </list-item>
          <list-item>
            <p>Cough</p>
          </list-item>
          <list-item>
            <p>Flu-like symptoms</p>
          </list-item>
          <list-item>
            <p>GERD</p>
          </list-item>
          <list-item>
            <p>Bronchoconstriction</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17405.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="order">
          <list-item>
            <p>Known hypersensitivity to alprostadil or components of the dosage form.</p>
          </list-item>
          <list-item>
            <p>Sickle cell disease or trait, multiple myeloma, leukemia, polycythemia vera, thrombocythemia as these conditions are known to precipitate priapism, and alprostadil can also predispose to prolonged erection or priapism.</p>
          </list-item>
          <list-item>
            <p>Peyronie disease of the penis, as alprostadil, is known to cause penile fibrosis and may worsen the condition.</p>
          </list-item>
          <list-item>
            <p>Alprostadil intraurethral suppository; "medicated urethral system for erection" should be avoided in patients with urethral strictures as using it can cause further injuries to the penis.</p>
          </list-item>
          <list-item>
            <p>Clinicians should avoid using alprostadil as an intraurethral suppository in patients with urethritis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17405.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When starting alprostadil for a patient complaining of erectile dysfunction, certain things are to be kept in mind to prevent and for the early identification of adverse effects for better overall outcomes. Alprostadil is known to cause hemodynamic instability causing hypotension/hypertension, and flushing.&#x000a0;It is advisable to monitor blood pressure, heart rate, and temperature before and after the use of the drug. Alprostadil is also known to cause penile pathologies such as stricture formation, fibrosis, and hematoma formation at the site of injection. Regular examination by a physician and timely attention by one on the onset of discomfort can bring&#x000a0;about better possible outcomes. For a better understanding of drug-to-effect response, monitoring&#x000a0;the duration of erection can be essential for tailoring management for the patient.</p>
      </sec>
      <sec id="article-17405.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The use of alprostadil for the treatment of erectile dysfunction in men has correlations with prolonged erection, and sometimes priapism.&#x000a0;The incidence of priapism as an adverse effect of alprostadil is more common with the intraurethral suppository, and priapism is a genitourinary emergency that requires detailed evaluation. The evaluation is primarily based on physical exam and possibly with the help of penile ultrasonography and penile blood gas analysis. Some of the management techniques include aspiration of cavernosal blood, cold saline irrigation, and penile injections with sympathomimetic agents.<xref ref-type="bibr" rid="article-17405.r17">[17]</xref>&#x000a0;Penile prosthesis implantation for priapism is also commonly used.<xref ref-type="bibr" rid="article-17405.r18">[18]</xref></p>
      </sec>
      <sec id="article-17405.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing erectile dysfunction with alprostadil as an intracavernosal injection or as an&#x000a0;intraurethral suppository requires an interprofessional team of healthcare providers, including a nurse, pharmacist, and several physicians in different specialties. Apart from classical causes of erectile dysfunction such as diabetes mellitus, hypertension, other common lifestyle factors such as obesity, limited or absence of physical exercise, lower urinary tract system infections are also linked to the development of erectile dysfunction requiring attention. Without proper management and patient education, the morbidity associated with the treatment itself can be dreadful. Patient education for the use of alprostadil as an intracavernosal injection form or as an intraurethral suppository is a must and is an essential aspect of the management. The patient should be monitored timely for the adverse effects of the drug, such as prolonged erection/priapism, penile fibrosis, urethritis, and penile fibrosis or stricture formation, and circulatory disturbances causing hypotension. Consult with a radiologist, urologist, to assess any penile pathology before starting alprostadil. Consult with a psychiatrist to&#x000a0;evaluate&#x000a0;for possible psychiatric issues that might&#x000a0;cause erectile dysfunction. Consult a sex therapist for holistic management of erectile dysfunction. Consult a cardiologist as studies have shown an association of cardiovascular diseases with erectile dysfunction (ED), whereas ED can be a strong indicator of CAD (coronary artery disease), and the recommendation is for cardiovascular assessment of a noncardiac patient in a patient coming with the chief complaint of erectile dysfunction.<xref ref-type="bibr" rid="article-17405.r19">[19]</xref> Also, using alprostadil can cause circulatory issues causing hypotension.</p>
        <p>Pharmacists should be ready to counsel patients on the proper use of the intracavernous and suppository formulations since they require the patient to have solid administration technique skills. If the pharmacist has any concerns about the patient's ability to self-administer the drug, or there are drug interactions on the medication review, they should contact the prescribing physician promptly. Nurses can also give counsel, and determine adherence and regimen effectiveness on follow-up visits, and check for any adverse medication effects, reporting any concerns to the physician. Only with this type of interprofessional team approach can alprostadil therapy be most effective. [Level V]</p>
        <p>Patients discussing&#x000a0;reproductive&#x000a0;health, particularly men, can be challenging, and it is essential to be empathetic and maintain a professional attitude while establishing a rapport. Creating a positive and respectful approach for patient and provider, allows there to be an open discussion&#x000a0;for subject matters such as erectile dysfunction.</p>
      </sec>
      <sec id="article-17405.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17405&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17405">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17405/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17405">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17405.s11">
        <title>References</title>
        <ref id="article-17405.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanchanale</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eardley</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Alprostadil for the treatment of impotence.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-8</page-range>
            <pub-id pub-id-type="pmid">24369066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieillard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eychenne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Astier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yiou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deffaux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction.</article-title>
            <source>Ann Pharm Fr</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>358</fpage>
            <page-range>358-63</page-range>
            <pub-id pub-id-type="pmid">24075706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coceani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Olley</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Bishai</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bodach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nashat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandins and the control of muscle tone in the ductus arteriosus.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>1977</year>
            <volume>78</volume>
            <fpage>135</fpage>
            <page-range>135-42</page-range>
            <pub-id pub-id-type="pmid">899912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aykanat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yavuz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>&#x000d6;zalkaya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Top&#x000e7;uo&#x0011f;lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oval&#x00131;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Karatekin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-4</page-range>
            <pub-id pub-id-type="pmid">26260095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>PGE1 improves diabetic peripheral neuropathy in patients with type 2 diabetes.</article-title>
            <source>Prostaglandins Other Lipid Mediat</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>126</volume>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">27421690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kielbasa</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Topical alprostadil treatment of female sexual arousal disorder.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>40</volume>
            <issue>7-8</issue>
            <fpage>1369</fpage>
            <page-range>1369-76</page-range>
            <pub-id pub-id-type="pmid">16757679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marasini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Massarotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bottasso</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Papa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maglione</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Comina</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Maioli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2004</year>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-6</page-range>
            <pub-id pub-id-type="pmid">15370722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshihara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin E1 Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature.</article-title>
            <source>Pain Pract</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-56</page-range>
            <pub-id pub-id-type="pmid">25612248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <day>21</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1045</fpage>
            <pub-id pub-id-type="pmid">28432310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neves-Zaph</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase Diversity and Signal Processing Within cAMP Signaling Networks.</article-title>
            <source>Adv Neurobiol</source>
            <year>2017</year>
            <volume>17</volume>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">28956327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lea</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.</article-title>
            <source>Drugs Aging</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-74</page-range>
            <pub-id pub-id-type="pmid">8785470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becher</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Topical alprostadil cream for the treatment of erectile dysfunction.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>623</fpage>
            <page-range>623-32</page-range>
            <pub-id pub-id-type="pmid">15013930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porst</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction.</article-title>
            <source>Int J Impot Res</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>187</fpage>
            <page-range>187-92</page-range>
            <pub-id pub-id-type="pmid">9442415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mantovani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Alprostadil plus Vacuum (VITARUM) in severe erectile dysfunction (ED).</article-title>
            <source>Arch Ital Urol Androl</source>
            <year>2017</year>
            <month>Jun</month>
            <day>30</day>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-147</page-range>
            <pub-id pub-id-type="pmid">28679188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacione</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Macedo</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Baptista-Silva</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment for Buerger's disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Mar</month>
            <day>11</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD011033</fpage>
            <pub-id pub-id-type="pmid">26967103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porst</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Transurethral alprostadil administration with MUSE ("Medicated Urethral System for Erection"). Current overview and personal experiences].</article-title>
            <source>Urologe A</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>410</fpage>
            <page-range>410-6</page-range>
            <pub-id pub-id-type="pmid">9738294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Podolej</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Babcock</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Emergency Department Management Of Priapism.</article-title>
            <source>Emerg Med Pract</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-16</page-range>
            <pub-id pub-id-type="pmid">28027457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000fc;cel</surname>
                <given-names>&#x000d6;B</given-names>
              </name>
              <name>
                <surname>Paz&#x00131;r</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kad&#x00131;o&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Penile Prosthesis Implantation in Priapism.</article-title>
            <source>Sex Med Rev</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>310</fpage>
            <page-range>310-318</page-range>
            <pub-id pub-id-type="pmid">28916463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17405.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shamloul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Erectile dysfunction.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Jan</month>
            <day>12</day>
            <volume>381</volume>
            <issue>9861</issue>
            <fpage>153</fpage>
            <page-range>153-65</page-range>
            <pub-id pub-id-type="pmid">23040455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
